prikaz prve stranice dokumenta The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
  Preuzmi
PDF 189.6 KB
Znanstveni rad - Izvorni znanstveni rad
The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
Croatian Medical Journal, 61 (2020), 2; 93-99. https://doi.org/10.3325/cmj.2020.61.93
Bukvić Mokos, Zrinka; Petković, Mikela; Balić, Anamaria; Marinović, Branka

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Bukvić Mokos, Z., Petković, M., Balić, A. i Marinović, B. (2020). The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study. Croatian Medical Journal, 61. (2), 93-99. doi: 10.3325/cmj.2020.61.93

Bukvić Mokos, Zrinka, et al. "The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study." Croatian Medical Journal, vol. 61, br. 2, 2020, str. 93-99. https://doi.org/10.3325/cmj.2020.61.93

Bukvić Mokos, Zrinka, Mikela Petković, Anamaria Balić i Branka Marinović. "The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study." Croatian Medical Journal 61, br. 2 (2020): 93-99. https://doi.org/10.3325/cmj.2020.61.93

Bukvić Mokos, Z., et al. (2020) 'The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study', Croatian Medical Journal, 61(2), str. 93-99. doi: 10.3325/cmj.2020.61.93

Bukvić Mokos Z, Petković M, Balić A, Marinović B. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study. Croatian Medical Journal [Internet]. 30.04.2020. [pristupljeno 26.12.2024.];61(2):93-99. doi: 10.3325/cmj.2020.61.93

Z. Bukvić Mokos, M. Petković, A. Balić i B. Marinović, "The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study", Croatian Medical Journal, vol. 61, br. 2, str. 93-99, Travanj 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:598782. [Citirano: 26.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:598782
Podaci o radu
Naslov (engleski)The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
AutorZrinka Bukvić Mokos
MBZ: 279423
AutorMikela Petković
AutorAnamaria Balić
AutorBranka Marinović
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA DERMATOVENEROLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Dermatovenerologija
Sažetak (engleski)
Aim: To evaluate the association between the use of dipeptidyl peptidase-4 inhibitors (DPP4I) and clinical and laboratory findings of bullous pemphigoid (BP) in patients treated at the European Reference Network - Skin Reference Centre in Croatia. ----- Methods: This retrospective study enrolled 82 patients treated for BP at the Department of Dermatovenereology, University Hospital Center Zagreb from January 2015 to December 2019. Clinical features of BP, presence of comorbidities, and laboratory findings of anti-BP antibodies and eosinophilia were analyzed in three groups of BP patients: 1) diabetes mellitus (DM) type II patients treated with DPP4I, 2) DM type II patients not treated with DPP4I, and 3) non-DM type II patients. ----- Results: The average age and anti-BP180 titer were similar in all three groups. DPP4I group had a slightly lower eosinophil level in both peripheral blood (4.89%) and biopsy specimens (87.5%), but the difference was not significant. The prevalence of inflammatory BP in DPP4I group was 76.5%. DPP4I group had significantly higher percentage of patients with chronic renal failure and dementia (52.9% and 11.8%, respectively) compared with non-DPP4I DM (14.3% and 0%, respectively) and non-DM type II patients (15.7% and 0%, respectively). ----- Conclusion: BP patients treated with DPP4I and those not treated with DPP4Is did not significantly differ in laboratory findings. However, DPP4I treatment was associated with an inflammatory subtype of BP and a higher prevalence of dementia and chronic renal failure. These findings warrant further research into the association of BP and DM with dementia and chronic renal failure.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCroatian Medical Journal
Brojčani podacivol. 61, br. 2, str. 93-99
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2020.61.93
URN:NBNurn:nbn:hr:105:598782
Datum objave publikacije2020-04-30
URL dokumentahttp://www.cmj.hr/2020/61/2/32378375.htm
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2020-10-27 12:49:01